Lumosa Therapeutics Announces FDA Clearance of IND Application Its LT3001, a New Drug for the Treatment of Acute Ischemic Stroke, for Multi-dose Phase 2 Trial in Combination with Mechanical Thrombectomy

Lumosa CEO's Interview by Kevin Price on the Price of Business Show

Lumosa Therapeutics Announces Positive Result from LT3001 Phase 2A Clinical Trial in Acute Ischemic Stroke

LT3001 represents a completely novel drug design in stroke treatment -- combining thrombolytic and neuroprotective properties into a single molecule which may confer unique efficacy and safety properties permitting a brand new perspective to the AIS patients.　

Lumosa and DONGWHA Enter Exclusive Distributorship Agreement for LT1001 in Korea – Securing a Foot in Northeast Asia and Increase Global Licensing Value

Formulation Patent for LT1001, An Extended-Release Analgesic Injection, Granted by Chinese Patent Office

Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection

(May 25th, 2021, Taipei) Lumosa Therapeutics is pleased to announce today the execution of an exclusive distribution agreement with PrJSC Pharmaceutical Firm Darnitsa (“Darnitsa”) for LT1001 in Ukraine. Darnitsa is one of the largest pharmaceutical companies in Ukraine. The company develops, manufactures, and markets generic, prescription, and over-the-counter products in several therapeutic areas including pain management. According to the agreement, Darnitsa is responsible for the registration, sales, and marketing of LT1001 in Ukraine, and Lumosa will supply LT1001 drug product. Lumosa is looking forward to working with Darnitsa to bring this unique product to the Ukrainian analgesic market, as well as gaining possible access to the Eastern European countries and Commonwealth of Independent States.